Pharming Group Notice of 9M Results

Thursday, 28 October 202113:30CET/07:30ETPlease note, the Company will only take questions from dial-in attendees. Thursday,28 October 202113:30CET / 07:30ET Please note, the Company will only take questions from dial-in attendees. Dial-in details:  Netherlands(Local)        085 888 7233 United Kingdom              0800 640 6441 United Kingdom(Local)  020 3936 2999 United States(Local)      +1 646 664 1960 All other locations           +44 20...

The Netherlands, 22/10/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

Netherlands (Local)        085 888 7233

United Kingdom              0800 640 6441

United Kingdom (Local)  020 3936 2999

United States (Local)      +1 646 664 1960

All other locations           +44 20 3936 2999

https://webcast.openbriefing.com/pharming-q321/

Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement and contact cascades in order to control inflammation in affected tissues.

Our lead product, RUCONEST®, is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema (HAE) attacks. We are commercializing RUCONEST® in the United States , the European Union and the United Kingdom through our own sales and marketing organization, and the rest of the world through our distribution network.

In addition, we are investigating the clinical efficacy of rhC1INH in the treatment of further indications, including pre-eclampsia, acute kidney injury and severe pneumonia as a result of COVID-19 infections.

We are also studying our oral precision medicine, leniolisib (a phosphoinositide 3-kinase delta, or PI3K delta, inhibitor), for the treatment of activated PI3K delta syndrome, or APDS, in a registration enabling Phase 2/3 study in the United States and Europe .

Furthermore, we are leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies, most notably for Pompe disease, which is currently in preclinical development.

Sijmen de Vries, CEO: T: +31 71 524 7400
Susanne Embleton , Investor Relations Manager: T: +31 71 524 7400 E: investor@pharming.com

Victoria Foster Mitchell / Alex Shaw
T: +44 203 727 1000

Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg